TROKE is the most common cause of disability in the US and one of the leading causes of mortality and disability in the world. 7, 8 The hope that damage to the central nervous system can be reversed or attenuated by cellular delivery techniques is the central idea behind neural repair using neural transplantation as a treatment after stroke. 15, 19, 24 Since 1992 several laboratories have attempted neural cell transplantation for stroke, mainly in rodent models. 2,9-12, 14,18-20,25 The extensive damage associated with stroke requires an abundant, stable, and safe source of cells in order to attempt successful neurorepair. Brannen and Sugaya 4 were able to culture and differentiate fetal origin HNSCs. When implanted into older rats, these cells survived, migrated, and improved the behavioral capabilities of the animals.
TROKE is the most common cause of disability in the US and one of the leading causes of mortality and disability in the world. 7, 8 The hope that damage to the central nervous system can be reversed or attenuated by cellular delivery techniques is the central idea behind neural repair using neural transplantation as a treatment after stroke. 15, 19, 24 Since 1992 several laboratories have attempted neural cell transplantation for stroke, mainly in rodent models. 2,9-12, 14,18-20,25 The extensive damage associated with stroke requires an abundant, stable, and safe source of cells in order to attempt successful neurorepair. Brannen and Sugaya 4 were able to culture and differentiate fetal origin HNSCs. When implanted into older rats, these cells survived, migrated, and improved the behavioral capabilities of the animals. 21 Translation of first-in-class therapies to the clinic, especially those involving invasive surgical procedures, require assessment of feasibility, efficacy, and safety in nonhuman primate models. 1 Our group has developed a stable chronic stroke model in macaque monkeys by open occlusion of the MCA. 23 Taking advantage of this model, we performed transplantation of HNSCs 7 days after the induction of stroke. Our goal was to demonstrate the feasibility of this approach and assess graft survival in the hostile environment of the stroke brain. To our knowledge, this is the first report of neural cell transplantation in a nonhuman primate model of stroke.
Materials and Methods
The study was performed in accordance with federal and National Institutes of Health guidelines for proper animal care, and with the approval of the Institutional Animal Care and Use Committee.
Three adult cynomolgus monkeys (Macaca fascicularis) (10-13 years old, 6-8 kg) received a unilateral occlusion of the M 1 segment of the right MCA. 23 One week later each animal received MR image-guided stereotactic intracerebral injections 16 of HNSC neurospheres labeled with BrdU. Four injection sites were selected in the precommissural, commissural, and postcommissural putamen and the thalamus, all in the penumbral region, medial to the center of the stroke area. All injections were separated by 3 to 4 mm in the coronal plane. To assess cell migration, a fifth injection was placed in the caudate nucleus adjacent to the lateral ventricle. All injections were performed through a 25-l syringe (needle gauge 22; Hamilton Company, Reno, NV) attached to an automatic pump with a delivery rate of 2 to 10 l/minute. Each selected target received 10 l containing two neurospheres (50,000-100,000 cells per neurosphere).
(For a description of cell preparation, see Brannen and Sugaya 4 and Qu, et al. 21 ) The needle was left in situ for an additional 6 minutes to allow the cells to diffuse from the needle tip. On the day of the HNSC surgery and throughout the study, the monkeys received oral cyclosporine (10 mg/kg twice a day). Magnetic resonance imaging conducted before and after surgical procedures was performed on a 3-tesla MR imaging unit (3T94 Signa VHi; General Electric Healthcare, Milwaukee, WI). 23 Behavioral evaluations to assess stroke and graft-related complications included a neurological evaluation using a "stroke" rating scale, a fine motor skill task, and a motor planning task. 23 After the final imaging sessions at 45, 75, and 105 days after transplantation, the monkeys were anesthetized with intravenous administration of pentobarbital (25 mg/kg), and perfused transcardially with a 0.9% saline solution followed by a 4% paraformaldehyde fixative. The brains were cut into slabs in the coronal plane, postfixed for 48 hours, cryoprotected, and then cut while frozen into 40-m sections using a sliding knife microtome. 5, 23 One series of sections of each brain was stained for BrdU (1:500; Accurate, Westbury, MA) reactivity using standard immunohistochemical procedures 6 and quantified using an unbiased, stereological cell counting method (MicroBrightField, Inc., Williston, VT). 5 To evaluate whether the BrdU-immunoreactive cells colocalized with undifferentiated or differentiated cells, we used double-labeling immunofluorescence procedures. The markers included nestin, for identification of immature neurons and astrocytes (1:550; BD Transduction Laboratories, Lexington, KY); ␤III-tubulin, for young neurons (R&D Systems, Minneapolis, MN); NeuN, for mature neurons (1:1000; Chemicon, Temecula, CA), and glial fibrillary acidic protein, for mature astrocytes (1:1000; DAKO, Glostrup, Denmark). Colocalization of BrdU and CD68 (a macrophage antigen) (1:3000; DAKO) was also evaluated. Immunofluorescence double-labeled sections were examined by using a laser scanning confocal microscope (Olympus, Tokyo, Japan).
Immunohistochemical controls consisted of deletion of first or secondary antibodies. For general anatomical evaluation, additional sections were stained for Nissl substance using cresyl violet acetate.
Results
After the right MCA occlusion, MR images revealed a cortical and subcortical infarction in the right MCA distribution area ( Figs. 1 and 2 ). The animals developed spastic left hemiparesis, left facial weakness, left visual field deficit, decreased responsiveness to their environment, and impaired gait and balance. Similar to our previous observations, 23 a gradual improvement in all behavioral tests was seen during the first months after surgery, without complications after grafting.
Our immunosuppression protocol produced plasma levels of cyclosporine equivalent to or higher than the ones used in the clinic (50-300 ng/ml). We measured cyclosporine levels and weighed the animals weekly.
Postmortem morphological analysis of Nissl-stained sections confirmed the stroke-related lesioned area in both cortical and subcortical structures. These regions were characterized by necrosis and loss of tissue (Fig. 2) . Needle tracks were easily detectable without traces of bleeding or infections. There was no disruption of brain structure in areas of HNSC grafting or evidence of HNSC proliferation and tumor formation.
In all the animals there was evidence of survival of transplanted cells (Figs. 3 and 4) . Tracks of dark, homogeneously stained, oval-shaped BrdU-immunoreactive nuclei were visible within the cortex and in the caudate, putamen, thalamus, and globus pallidus. Few cells were observed immediately adjacent to the stroke area. Cells that were immunoreactive to BrdU were also found in white matter close to the injection site (for example, in the internal capsule). A few cells per field demonstrated granular staining and irregular shape, similar to nuclei undergoing apoptosis or engulfed by macrophages, especially in Case 7065. Stereological cell counts revealed differences in the number of BrdU-positive cells between monkeys. Case 7112 (killed at 45 days) had a total of 14,833.68 BrdU-positive cells. Case 7063 (killed at 75 days) had 75,372.88, and Case 7065 (killed at 105 days) had 18,317.76. Considering that each monkey received approximately 250,000 to 500,000 cells, the survival rates were 3 to 6% (Case 7112), 15 to 30% (Case 7063), and 3.7 to 7.3% (Case 7065).
Colocalization of nestin and BrdU immunofluorescence was observed, suggesting a central nervous system fate for the double-stained HNSCs (Fig. 5) . Intense nestin immunofluorescence without BrdU colocalization was also found in the injection sites, probably associated with host astroglia proliferation. Colocalization of BrdU, glial fibrillary acidic protein, and NeuN immunofluorescense failed to reveal a mature phenotype in grafted cells. HNSCs, preferentially located away from the immediate injection site (Fig. 6) . The presence of ␤III-tubulin in these cells is indicative of an immature neuronal phenotype.
Staining with CD68, a marker for macrophage lineage, revealed an infiltrate in the area surrounding the stroke. Most of the CD68-positive cells were seen in the white matter tracts, where the infiltrate extended far outside the immediate stroke area, such as in the internal capsule ( Fig. 7A  and B ). This pattern probably represents reaction to the death of axons that originated in the stroke area. The graft tracts had a marked infiltrate with CD68-positive cells (Fig.  7C and D) . This host reaction occurred despite treatment with cyclosporine and may explain the relatively low graft survival in this and probably many other studies.
Discussion
Our results in a model of stroke in nonhuman primates demonstrate that HNSCs can survive for up to 105 days when transplanted 1 week after an ischemic event and in part undergo neuronal differentiation. The animals survived the stroke, and no complications occurred after grafting. Our data also suggest a modest migration of some of the transplanted cells outside the injection site, but not the expansive migration that can be seen after grafting of HNSCs in models of stroke in rodents. 13, 17 In this experiment, we transplanted cells close to the infarcted area and 1 week after the infarction, based on the hypothesis that grafted cells may affect the survival of remain-
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Transplantation in a nonhuman primate model of stroke ing host neurons and modulate reactive astrogliosis. There are several advantages to this approach. First, because a glial scar begins forming about 1 week after the stroke, 3 by grafting early we intended to facilitate graft integration into the damaged host tissue before an astrocytic scar had been established. Second, targeting is facilitated, because the infarction area can be clearly delineated 1 week after the stroke event by using MR imaging. Third, this is a realistic model of the potential clinical application of this treatment strategy, because invasive surgical procedures are not performed in patients until clinical stabilization occurs and standard procedures such as reperfusion have been exhausted. The disadvantage of our "early and close" transplantation method is that the graft encounters a hostile environment that may affect cell survival. The target area may have poor perfusion and in theory may have an active inflammatory process. Our results from staining with CD68 revealed that the macrophage infiltrate did not extend indiscriminately around the stroke but concentrated along white matter tracts and in the graft areas. For example, there were few CD68-positive cells in the putamen of any of the animals. We assume that the infiltrate was a specific reaction to the degenerating axons in the case of the white matter and to the xenograft in the case of graft tracks. Low survival rates of transplanted stem cells into the brain have been observed in other animal paradigms. 11, 18 The low survival rate in our study (3-30%) does not differ from others, particularly in the case of a xenograft. We can expect better results with allografts. It can be argued that a more aggressive immunosuppression therapy may have improved cell survival. Yet, the utilized protocol (10 mg/kg orally twice daily) produced plasma levels of cyclosporine equivalent to or higher than the ones used in the clinic (50-300 ng/ml).
Various strategies can be used in the future to improve the present outcome. Targeting toward the boundaries of the penumbra with normal host tissue and better oxygenation might ensure more satisfactory graft survival. Adding steroids to the protocol may also help decrease edema and inflammation.
We found that few BrdU-positive cells migrated to the area of stroke. These results differ from those in rodent studies, where migration of grafted stem cells across large distances has been described. 21 Different stem cell clones may respond differently to the host brain, and the model of stroke used (temporary versus permanent stroke) may affect the local environment. Furthermore, the complexity of the primate brain presents natural obstacles that may affect migration, such as the presence of the internal capsule in the striatum, as well as longer distance to cover due to the larger size of the brain, 22 compared with the rodent brain. The behavioral follow up revealed no complications associated with the grafting procedure. Although partial improvement of the syndrome was observed, no further conclusions can be drawn at this time because in this feasibility study there were no controls, and partial improvement is part of the natural history of stroke. 23 Stem cell transplantation alone is not likely to result in restoration of lost neural structures, although it may be part of a reparative therapy integrated with additional therapies, such as the use of trophic factors. In fact, grafted neural stem cells may also act through secretion of trophic factors that can potentially improve the survival and recovery of host neurons. Based on the information about HNSC survival obtained in these animals, a large controlled project to assess behavioral improvements is warranted in the future.
Conclusions
Our results demonstrate that HNSCs can be safely transplanted 1 week after stroke induced by MCA occlusion. Surviving graft was seen 105 days after the transplantation. Some of the transplanted cells were undergoing neuronal differentiation and were probably migrating out of the cluster of grafted cells. Further study with a variety of graft sources and a larger number of animals is necessary to allow for controlled behavioral testing.
